Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 82.57% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 376.81% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 9.25% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -38.10% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 38.94% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 152.82% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 203.80% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 153.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 153.72% |
| Mar 31, 2026 | -125.59% |
| Dec 31, 2025 | 5,044.94% |
| Sep 30, 2025 | 392.06% |
| Jun 30, 2025 | 2,800.13% |
| Mar 31, 2025 | 48.70% |
| Dec 31, 2024 | 37.84% |
| Sep 30, 2024 | 139.20% |
| Jun 30, 2024 | 92.10% |
| Mar 31, 2024 | -13.10% |
| Dec 31, 2023 | 61.14% |
| Sep 30, 2023 | 35.98% |
| Jun 30, 2023 | 31.14% |
| Mar 31, 2023 | 39.04% |
| Dec 31, 2022 | 27.38% |
| Sep 30, 2022 | -37.98% |
| Jun 30, 2022 | -6.78% |
| Mar 31, 2022 | -27.98% |
| Dec 31, 2021 | 21.36% |
| Sep 30, 2021 | 38.48% |